CAR T-cell therapies combine cellular therapy, gene therapy and immune therapy to use a patient’s own T-cells to fight cancers. It is this potential for harnessing our immune systems to fight cancer that makes CAR T-cell therapies so revolutionary and earns them the name, “living drugs”.

Syngene is contributing to this revolutionary field by helping our clients evaluate their novel medicines/molecules for their mode of action, in vivo functional efficacy and other vital characteristics.  Our end-to-end in vitro and in vivo immuno-oncology assessment platform allows fast and accurate validation of treatment approaches.

Our capabilities in supporting CAR-T cell research

• Design of CAR constructs
• CRISP-R gene editing
• Primary T-cell assays
  • Human PBMCs isolation, sorting
  • Cytotox assay with co-cultured cancer cells
  • Proliferation
  • Cytokine profile
• Virus generation for CAR delivery
  • Lentivirus packaging
  • Transduction efficiency
• Efficacy studies in syngeneic models
• Ex-vivo immuno-phenotyping of TILs
• PDX and humanized mouse models
• Preclinical evaluation
  • In vivo proliferation of effector cells: CAR expression and CFSE assay
  • Xenograft tumor growth inhibition (NOG-SCID mice)
  • Survival as endpoint
  • Whole animal imaging — Biodistribution
• Biorepositories
  • Collaboration with multiple local and national medical centers for healthy and patients’ samples (blood, tissues)
  • Currently banking >200 healthy donor PBMC ready to use